Physician profile
Robert Alexander
NPI 1285688309
$7,507.96
in general payments reported to CMS, 2019-2025
41 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $559 · 2021: $424 · 2022: $831 · 2023: $1,364 · 2024: $1,673 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,862.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,977.21 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,700.34 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.80 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Philips North America LLC | $371.11 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (5050) Extended Holter |
| Mylan Specialty L.P. | $330.54 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $225.80 | 2019-2025 | |
| Grifols USA, LLC | $185.44 | 2019-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $172.73 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $170.92 | 2024-2025 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $147.92 | 2021-2025 | Dupixent |
| Insmed, INC. | $141.07 | 2022-2025 | Arikayce, Brinsupri |
| Advanced Respiratory, INC | $129.95 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $111.75 | 2019 | |
| Harmony Biosciences LLC | $100.63 | 2023-2025 | Wakix |
| Merck Sharp & Dohme LLC | $98.48 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $88.06 | 2021-2025 | |
| United Therapeutics Corporation | $83.22 | 2023-2025 | Tyvaso, Tyvaso |
| Vifor Pharma, INC. | $75.17 | 2024-2025 | Zemaira |
| Inspire Medical Systems, INC. | $70.90 | 2023-2025 | Inspire |
| Verona Pharma, INC. | $70.75 | 2025 | Ohtuvayre |
| Optinose US, INC. | $58.73 | 2019-2022 | |
| Shire North American Group INC | $53.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.03 | 2022-2024 | Glassia |
| Lilly USA, LLC | $44.57 | 2024-2025 | Zepbound, Mounjaro |
| Electromed, INC. | $43.01 | 2024 | Smartvest |
| Neurocrine Biosciences, INC. | $33.62 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.40 | 2023 | Opsumit |
| Mallinckrodt Hospital Products INC. | $30.29 | 2020-2023 | Acthar |
| Aerin Medical INC. | $29.16 | 2024 | |
| Itamar Medical INC | $29.14 | 2024 | Watchpatone |
| Teva Pharmaceuticals USA, INC. | $28.81 | 2020-2022 | |
| Viatris Specialty LLC | $20.14 | 2025 | Yupelri |
| Zoll Respicardia, INC. | $16.24 | 2025 | Remede System |
| Baxter Healthcare | $15.84 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Alkermes, INC. | $15.67 | 2024 | Vivitrol |
| Amgen INC. | $15.13 | 2023 | Tezspire |
| Janssen Pharmaceuticals, INC | $14.53 | 2019 | |
| Pfizer INC. | $14.50 | 2022 | |
| Novo Nordisk INC | $13.87 | 2024 | Wegovy |
| Genentech USA, INC. | $13.70 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.